March 02, 2015 11:06 PM ET

Life Sciences Tools and Services

Company Overview of ForteBio, Inc.

Company Overview

ForteBio, Inc. develops instrumentation for biotherapeutic drug discovery and development. It offers analytical systems that enable real-time analysis of biomolecular interactions, such as protein quantification and characterization of protein-protein interactions, etc. in micro-volume sample sizes. The company offers Octet systems that include instruments, biosensors, reagents, and assay kits for the analysis of biomolecular interactions, as well as to enable real-time and label-free analysis for the determination of affinity, kinetics, and concentration. Its Octet systems also enable large molecule characterization and small molecule and fragment analysis. The company also offers BlItz Sys...

1360 Willow Road

Menlo Science & Technology Park

Suite 201

Menlo Park, CA 94025

United States

Founded in 2001

Phone:

650-322-1360

Fax:

650-322-1370

Key Executives for ForteBio, Inc.

Chief Executive Officer, President and Director
Age: 61
Vice President of Product Development & Operations and General Manager
Age: 44
Vice President of Sales
Age: 44
Vice President of China Operations
Executive Officer
Age: 55
Compensation as of Fiscal Year 2014.

ForteBio, Inc. Key Developments

ForteBio, Inc. Launches New Interaction Analysis System

ForteBio, Inc. has launched the Octet HTX system, the new member of the Octet line of label-free interaction analysis systems. The Octet HTX system addresses the acute industry need for increased analysis speed and sample throughput when characterizing large numbers of therapeutic candidates, the company said. Octet systems provide unique insights into drug-target binding interactions, insights that are used to fine-tune the affinity and specificity of drug molecules. The Octet HTX instrument performs kinetic analysis of up to 96 binding interactions simultaneously, a capability offered by no other stand-alone label-free platform. In addition, the Octet HTX performs full 96-well plate determinations of protein concentrations in as little as 2 minutes.

Avacta Group plc Announces Expansion of Collaboration with Fortebio

Avacta Group plc announced that it has extended its commercial collaboration with ForteBio. Avacta has entered into a distribution agreement with ForteBio for the sale of Optim, the group's protein analysis product, in China, Hong Kong and Taiwan. Optim has been developed to accelerate and reduce the cost of drug development by providing early analysis of compounds to identify the best candidates and to define the optimal processing conditions.  In the critical stages of pre-formulation, stability testing and formulation of biopharmaceutical drugs, Optim delivers vital information tens of times faster than other approaches, using sample sizes less than a hundredth the size of those needed by existing techniques. Optim comprises a benchtop instrument, analysis software and a single-use sample holder that leads to recurring consumables revenues.

Similar Private Companies By Industry

Company Name Region
Acceleration Laboratory Services, Inc United States
Buffalo Clinical Research Center, LLC United States
ACR Image Metrix, LLC United States
PanGenX, Inc. United States
Integrated DNA Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ForteBio, Inc., please visit www.fortebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.